Continuous bioprocessing for biologics manufacturing
September 17-21, 2017
Various strategies are explored for continuous bioprocessing for manufacturing of recombinant proteins and monoclonal antibodies: 1. continuous perfusion culture plus batch product capture; 2. continuous perfusion culture plus semi-continuous product capture; 3. continuous perfusion culture plus continuous product capture (Figure 1). Our main focus has been on the several initial unit operations: high cell concentration perfusion cell cultures and early product capture steps, in order to realize its potentials of being flexible, improving product quality and lowering costs. These initial unit operations require large volumes and represent the most important part of this processing platform, where we can deliver the largest benefits.
Please click Additional Files below to see the full abstract.
Hang Zhou and Weichang Zhou, "Continuous bioprocessing for biologics manufacturing" in "Integrated Continuous Biomanufacturing III", Suzanne Farid, University College London, United Kingdom Chetan Goudar, Amgen, USA Paula Alves, IBET, Portugal Veena Warikoo, Axcella Health, Inc., USA Eds, ECI Symposium Series, (2017). http://dc.engconfintl.org/biomanufact_iii/100
This document is currently not available here.